Literature DB >> 29034817

Enhanced cytotoxic activity of effector T-cells against cholangiocarcinoma by dendritic cells pulsed with pooled mRNA.

Mutita Junking1, Janya Grainok1,2, Chutamas Thepmalee1,3, Sopit Wongkham4,5, Pa-Thai Yenchitsomanus1.   

Abstract

Cholangiocarcinoma is a malignancy of bile duct epithelia with an increasing in incidence rate worldwide. Surgery is the only curative treatment, while adjuvant chemotherapy and radiotherapy render poor responses. Cell-based immunotherapy is a potential strategy for cholangiocarcinoma treatment. However, variation of tumor antigens in cholangiocarcinoma leads to the ineffectiveness of cell-based immunotherapy. In this study, we examined the activation of effector T-cells by dendritic cells pulsed with protein lysate or total RNA from cholangiocarcinoma cell lines for their cytolytic activity against cholangiocarcinoma. Broad-spectrum antigen types with respect to RNA antigen sources were obtained from combination of three cholangiocarcinoma cell lines (KKU-213, KKU-100, and KKU-055). Compared with protein lysate-pulsed dendritic cells, total RNA-pulsed dendritic cells induced anti-tumor effector T-cell response with higher killing ability to KKU-100 and KKU-213 cells compared with protein lysate-pulsed dendritic cells. Moreover, pooled messenger RNA from three cholangiocarcinoma cell lines significantly increased the specific killing capacity of activated lymphocytes against KKU-213 cells. These results suggest that activation of anti-tumor effector T-cells against cholangiocarcinoma by RNA-pulsed dendritic cells is more effective than that by protein lysate-pulsed dendritic cells. In addition, pulsing dendritic cells with pooled messenger RNA from multiple cell lines enhanced the efficacy of a cellular immune response against cholangiocarcinoma.

Entities:  

Keywords:  Cancer immunotherapy; cholangiocarcinoma; dendritic cells; effector immune cells; intra-tumor heterogeneity

Mesh:

Substances:

Year:  2017        PMID: 29034817     DOI: 10.1177/1010428317733367

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  10 in total

Review 1.  Cholangiocarcinoma: novel therapeutic targets.

Authors:  Keisaku Sato; Shannon Glaser; Domenico Alvaro; Fanyin Meng; Heather Francis; Gianfranco Alpini
Journal:  Expert Opin Ther Targets       Date:  2020-02-26       Impact factor: 6.902

2.  Cholangiocarcinoma: what are the most valuable therapeutic targets - cancer-associated fibroblasts, immune cells, or beyond T cells?

Authors:  Juan Wang; Emilien Loeuillard; Gregory J Gores; Sumera I Ilyas
Journal:  Expert Opin Ther Targets       Date:  2021-12-03       Impact factor: 6.797

3.  Suppression of TGF-β and IL-10 receptors on self-differentiated dendritic cells by short-hairpin RNAs enhanced activation of effector T-cells against cholangiocarcinoma cells.

Authors:  Chutamas Thepmalee; Aussara Panya; Jatuporn Sujjitjoon; Nunghathai Sawasdee; Naravat Poungvarin; Mutita Junking; Pa-Thai Yenchitsomanus
Journal:  Hum Vaccin Immunother       Date:  2020-01-24       Impact factor: 3.452

4.  Antigen-loaded dendritic cells triggers a specific cytotoxic T lymphocytes immune response against hepatocellular carcinoma: in vitro study.

Authors:  N E El-Ashmawy; E A El-Zamarany; E G Khedr; H A El-Bahrawy; O A El-Feky
Journal:  Clin Transl Oncol       Date:  2018-10-27       Impact factor: 3.405

Review 5.  Intrahepatic cholangiocarcinoma: Morpho-molecular pathology, tumor reactive microenvironment, and malignant progression.

Authors:  Alphonse E Sirica; Mario Strazzabosco; Massimiliano Cadamuro
Journal:  Adv Cancer Res       Date:  2020-12-09       Impact factor: 6.242

Review 6.  The Functional Roles of Immune Cells in Primary Liver Cancer.

Authors:  Linh Pham; Konstantina Kyritsi; Tianhao Zhou; Ludovica Ceci; Leonardo Baiocchi; Lindsey Kennedy; Sanjukta Chakraborty; Shannon Glaser; Heather Francis; Gianfranco Alpini; Keisaku Sato
Journal:  Am J Pathol       Date:  2022-03-23       Impact factor: 5.770

7.  Honokiol-enhanced cytotoxic T lymphocyte activity against cholangiocarcinoma cells mediated by dendritic cells pulsed with damage-associated molecular patterns.

Authors:  Arunya Jiraviriyakul; Worawat Songjang; Pongsathorn Kaewthet; Phachsita Tanawatkitichai; Punyapat Bayan; Sutatip Pongcharoen
Journal:  World J Gastroenterol       Date:  2019-08-07       Impact factor: 5.742

Review 8.  The role of tumor-infiltrating lymphocytes in cholangiocarcinoma.

Authors:  Dong Liu; Lara Rosaline Heij; Zoltan Czigany; Edgar Dahl; Sven Arke Lang; Tom Florian Ulmer; Tom Luedde; Ulf Peter Neumann; Jan Bednarsch
Journal:  J Exp Clin Cancer Res       Date:  2022-04-07

9.  Dendritic cells loaded with CD44+ CT-26 colon cell lysate evoke potent antitumor immune responses.

Authors:  Changhao Fu; Ning Zhou; Yuanyuan Zhao; Jinyue Duan; Hao Xu; Yi Wang
Journal:  Oncol Lett       Date:  2019-10-02       Impact factor: 2.967

Review 10.  Cellular based immunotherapy for primary liver cancer.

Authors:  Yuanyuan Zheng; Yan Li; Jiao Feng; Jingjing Li; Jie Ji; Liwei Wu; Qiang Yu; Weiqi Dai; Jianye Wu; Yingqun Zhou; Chuanyong Guo
Journal:  J Exp Clin Cancer Res       Date:  2021-08-09
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.